Britain and America have announced a key commercial pact that will keep no duties on British drug exports being sold in the American market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has pledged to increase spending on medicines through the National Health Service (NHS). This commitment ensures that tariffs on these key products will stay at nothing for a duration of the next three years.
This deal follows recent statements to significantly raise duties on branded drug imports, with increases mentioned up to 100%.
"This arrangement between the UK reinforces the international landscape for new treatments and establishes much-needed fairness to American-British medicine commerce," a statement noted.
Commercial Significance
Pharmaceuticals constitute one of the UK's most significant export categories to the US, which is easily the biggest destination for large British pharmaceutical firms.
Trade data reveal that in the year prior to last September, the UK exported pharmaceutical products totaling £11.1bn to the US. This amount made up 17.4% of total UK exports in that period.
"This agreement protects jobs, boosts investment and paves the way for the UK to establish itself as a global hub for biotech and pharma," a government official remarked.
Specific British Pledges
The deal entails several specific pledges from the British government:
- Higher Cost Ceiling: The UK will raise the price threshold at which it considers new medicines to be too expensive by a quarter.
- Increased NHS Spending: There is a target to double total NHS spending on drugs from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Rebate Cap: The sum drug companies must refund to the NHS to stay within budget will be limited at fifteen percent. Last year, rebates were more than 20%.
Industry Background
The deal comes amid a long-running tension between the pharmaceutical industry and the UK government over medicine costs and approval rates.
These tensions were exacerbated by arguments that US customers were charged a premium for the equivalent treatments than patients in the Britain and the EU.
Recently, several significant drug company projects in the UK have been paused or scrapped, while substantial expansions have been pledged toward projects in the United States.
A senior figure publicly accepted that the NHS had to spend more on drugs, noting that its spending on drugs had decreased as a proportion of its overall budget over the previous ten-year period.
